Articles tagged with Bone Cancer
Researchers analyzed data from Washington State hospital database and found no difference in cancer rates between patients who received rhBMP and those who did not. The study's findings suggest that additional follow-up is needed to rule out any longer-term increase in cancer risk.
Researchers at Kyoto University's Yamada lab created a mouse model to study the EWS-FLI1 gene's role in bone cancer. The model revealed that other mutations are necessary for cancer development and that correcting osteogenic cell differentiation could prevent bone cancers.
According to a Norwegian study of male cancer patients diagnosed under the age of 25, many male cancer patients have problems reproducing. The researchers found that male cancer survivors are three times as likely to turn to assisted fertilization to have children as males with no cancer diagnosis.
A new antibody treatment has shown promise in blocking the process of bone degradation caused by osteosarcoma, a rare type of bone cancer. The treatment reduced bone degradation by up to 80% in a cancer mouse model, offering hope for reducing amputations among young patients.
A new study analyzed 527 patients who underwent spinal fusion surgery using recombinant human bone morphogenetic protein (rhBMP) and found high rates of successful fusion and low rates of complications. The study found no significantly increased risk of cancer, contradicting previous concerns.
Researchers at Rice University have developed a way to mimic the conditions under which cancer tumors grow in bones, enabling more accurate testing of cancer-fighting drugs. The study found that bone tumors exposed to normal forces express more of a protein called IGF-1 than detected in static cultures.
A clinical trial at University of Colorado Anschutz Medical Campus demonstrates an intervention that successfully reduces caregiver stress in cancer patients treated with stem cell transplantation. The study shows significant lower stress levels and improved quality of life for caregivers.
A new stem cell disease model reveals how a protein known to prevent tumor growth in most cases may drive bone cancer when genetic changes cause its overproduction. The study focused on rare genetic disease Li-Fraumeni Syndrome, which increases the risk of many cancers, including osteosarcoma.
Researchers found that bisphosphonate users were half as likely to develop endometrial cancer, suggesting a potential preventive effect. The study suggests that women taking bone-strengthening medications with increased endometrial cancer risk may benefit from nitrogen-form bisphosphonates.
A new study identifies Ewing sarcoma-associated transcript 1 (EWSAT1) as a critical target of the EWS-FLI1 fusion protein, contributing to cancer cell growth and repression of key genes. This finding supports the notion that long noncoding RNAs can drive cancer development and highlights an important mediator in Ewing Sarcoma.
Researchers redesigned a molecule to control immune cell activity, changing its target and altering the effects of its signal. This new approach may let scientists selectively block the bad signals that cause or contribute to disease, enhancing good signals that defend against cancer and infections.
A new mouse model reveals that high levels of Notch1 can transform osteoblasts into cancerous cells, leading to osteogenic sarcoma. This study supports the hypothesis that Notch activating mutations can act as a common triggering mechanism in bone cancer.
Research identifies RAS oncogene involvement in DS-ALL cases, highlighting genetic insights into leukemia risk in children with Down syndrome. Geneticists sequenced exomes of affected individuals, shedding light on disease characteristics.
Certain cancers have a characteristic age at which they occur, and their incidence decreases beyond that age. This 'developmental origin of disease hypothesis' suggests many cancers originate early in life, possibly before birth.
Researchers developed a drug-delivery system that targets bone cancer cells, reducing growth and prolonging survival in mice. The nanoparticles also stimulated healthy bone tissue growth, increasing strength and volume.
Professional surfer Richie Lovett has made a full recovery from clear cell chondrosarcoma, an uncommon form of bone cancer, thanks to pioneering surgical procedures. The groundbreaking technique developed by Dr. Earl Warren Brien removed the tumor and damaged bone in its entirety, replacing it with a prosthetic implant.
Researchers discover MGA controls expression of Bone Morphogenetic Proteins, a crucial step in bone development, and may contribute to tumor formation in adults. The study suggests that MGA's dysfunction could lead to chronic lymphocytic leukemia.
Researchers found that a simple questionnaire predicting lung involvement improves patient outcomes in chronic graft-vs.-host disease. A score of 3 indicates shortness of breath at rest or requiring oxygen, associated with higher mortality. Early detection enables timely treatment to reduce symptoms and improve survival.
Researchers identify diverse genetic risk factors for osteosarcoma in dogs, including known human cancer genes and novel findings. The study sheds light on the disease's mechanisms and potential connections to human bone cancer.
Cancer patients are at increased risk of bone disease and fractures due to the primary disease or treatment therapies. The IOF review emphasizes the importance of early evaluation and treatment with evidence-based pathways to prevent skeletal-related events and bone loss.
Scientists have identified two types of rare bone tumors linked to specific mutations in the H3F3A and H3F3B genes. These mutations are found in nearly 100% of patients suffering from chondroblastoma and giant cell tumor of the bone, offering a new diagnostic tool and potential treatment.
Researchers have identified a fibrous dysplasia tumor in a Neanderthal rib from Croatia, dating back over 120,000 years. This discovery predates previous evidence of this type of cancer by tens of thousands of years, challenging the notion that bone tumors were rare in ancient human populations.
Emanuel Hamelburg, a Boston-area prostate cancer survivor, has been recognized for his dedication to cancer awareness and advocacy. He was awarded the Survivor Circle Award by the American Society for Radiation Oncology (ASTRO) in 2012.
New research reveals that women with HER2 positive breast cancer that is also hormone (estrogen and progesterone) receptor negative have an increased risk of early death and less likely to recur in bone compared to those with hormone-sensitive cancer. The study suggests HR status defines two different subsets of HER2 positive cancers.
A simple three-question paper-and-pencil survey can effectively identify women experiencing symptoms that may indicate ovarian cancer. The study involved 1,200 women and found that the screening tool identified 5% of women with a positive symptom score, resulting in one diagnosis of ovarian cancer.
Researchers found a new pathway activated by FLT3 mutation in acute myeloid leukemia, leading to the activation of CDK1 and promoting cell differentiation. Clinical trials with CDK1 inhibitors are underway, suggesting therapies targeting this pathway may be effective for patients resistant to existing treatments.
A new study reveals that a combination of molecular imaging, radiography, and dual imaging probes detects more cancerous bone lesions than other methods. The addition of molecular imaging with combined radiopharmaceuticals to conventional CT improves the power of imaging for cancer diagnosis.
A team of researchers at Georgetown University Medical Center has discovered an agent that prevents the spread of osteosarcoma cancer to the lungs in mice with the disease. The agent, an ezrin inhibitor, targets a protein vital to the spread of osteosarcoma and may potentially treat adults and children with bone tumors.
Researchers discovered the expression of cancer-killer SAC-GFP activity in bone marrow cells after transplantation, suggesting successful transfer and colonization of anti-cancer tissue. The study shows promise for treating primary and metastatic tumors with genetically modified stem cells that secrete potent Par-4/SAC killer proteins.
Researchers at University of Minnesota discovered a gene pattern in dogs that distinguishes between aggressive and less aggressive forms of bone cancer. The finding may lead to the development of laboratory tests to predict tumor behavior in humans, allowing for tailored therapy and potentially reducing side effects.
Researchers are using genomic research to identify new genes that give rise to osteosarcoma and develop personalized blood tests to monitor disease in patients. The goal is to improve treatment of this difficult disease through better diagnosis and monitoring.
Dr. Hoang's research aims to understand and explain the underlying mechanisms of tumor progression in osteosarcoma, a type of aggressive bone cancer that often relapses with low survival rates. The award recognizes his work advancing knowledge on how to develop therapies for patients with untreatable sarcomas.
A new balloon kyphoplasty procedure provides rapid pain relief, increased mobility, and reduced need for painkillers compared to standard non-surgical care. Cancer patients with spinal fractures experience improved spinal function, quality of life, and pain during the study period.
23andMe has completed its Independent Sarcoma Scientific Advisory Committee, comprising leading researchers and clinicians, to advance understanding of sarcomas. The company aims to combine genetic data with patient-reported outcomes to find patterns in sarcoma biology and treatment response.
Researchers discover that chromosomal crisis is common in cancer development, causing hundreds of genome fragments and multiple mutations. The phenomenon is particularly common in bone cancers, where the ravaged genome can lead to increased cancer development.
A study led by Ohio State University found that a drug currently approved for osteoporosis treatment can reduce bone loss and tumor size in mice with oral cancer. The drug, zoledronic acid, was associated with smaller tumors and an increase in new bone formation.
A Florida State University researcher has developed a molecular sensor that accurately detects fluoride levels at very low concentrations, posing a carcinogenic risk. The sensor's nanomolar sensitivity makes it one of the most sensitive fluoride sensors known to date.
Researchers are investigating a theory that 'friendly bacteria' can kill bone cancer cells in osteosarcoma. Modifying Salmonella typhimurium to produce molecules that target cancer-causing molecules could lead to a more effective treatment for bone cancer.
A five-year study found significantly lower death rates from all causes and cancer in Paducah Gaseous Diffusion Plant workers compared to the US population. However, death from lymphatic and bone marrow cancers was slightly above national rates. Security workers had higher overall death rates than other employees.
A man and his two Great Pyrenees embark on a 2,000-mile walk to raise awareness about cancer in dogs while collecting DNA samples for a new $5.3 million canine cancer project. The TGen-VARI program aims to discover the causes of cancer in dogs and potentially translate findings to humans.
A new study from Michigan Medicine found that freezing breast tumors using cryoablation kills the cancer and generates an immune response that helps stop its spread, leading to improved survival rates. The rapid freezing technique appears to be more effective than slower techniques in killing metastases and improving survival.
Bone marrow transplantation can cause immune deficiency, leading to infections and cancer recurrence due to thymic damage from donor T cells. Research identified key molecules FasL and TRAIL required for this damage, offering potential targets to improve allo-BMT outcomes.
Researchers found that Bortezomib shuts down cellular machines that destroy Runx2, a protein complex that blocks the growth of bone cancer cells. The study suggests that Bortezomib may represent a new treatment option for osteosarcoma, a devastating disease that responds poorly to current chemotherapies.
A recent review suggests that limb-sparing surgery does not provide a significant benefit to patients with bone and soft tissue sarcomas. The study found that early and late complications are more common with limb-sparing surgery, but some advantages were seen for higher surgical sites in the lower limb, such as the hip.
Researchers at Vanderbilt University School of Medicine have discovered that inhibiting an enzyme called 11-beta-HSD2 blocks COX-2 activity in human and mouse colorectal tumor cells, potentially providing a new approach to preventing colorectal cancer. This finding is significant because long-term inhibition of 11-beta-HSD2 did not cau...
A new approach to treating bone loss, which blocks Wnt signaling pathway inhibitors, may increase the risk of bone cancer. This method is associated with dysregulated Wnt signaling, linked to several cancers.
Men who survived childhood leukemia treatment into adulthood have lower bone mineral density, increasing their risk of osteoporosis. The study found that male survivors were more likely than female survivors to have weaker bones, and shorter individuals also faced higher risks.
Delays in diagnosis of teenagers and young adults (TYAs) with cancer can range from four to 184 weeks, with the average time being 15.2 weeks. A study found that out of 207 young people with cancer, four out of five sought medical help quickly, while only seven per cent delayed for months.
Researchers at Johns Hopkins Kimmel Cancer Center found that cancer stem cells in multiple myeloma share properties with normal stem cells and exhibit resistance to chemotherapy. These cells contain high levels of enzymes that neutralize toxins, making them harder to treat.
A Mayo Clinic study shows cryoablation can provide durable pain relief for patients with bone metastases. Eighty percent of patients experienced significant pain reduction after the treatment, which also improved their quality of life.
Researchers found that bone marrow stem cells can take on the appearance of malignant cells but do not have the same cellular behavior, casting doubt on the theory that they seed cancer. This discovery has implications for cancer treatment and study methods.
Researchers at the University at Buffalo have discovered a significant association between chronic gum disease and the risk of tongue cancer. The study found that every millimeter of alveolar bone loss increases the risk five-fold, with no effect from other conditions.
A study found that men with chronic gum disease were at higher risk for tongue cancer, regardless of smoking status. Periodontitis was significantly associated with an increased risk of tongue cancer in a study of 51 white men.
A four-year study on pediatric osteosarcoma will investigate the effects of genes related to bone growth and lifestyle habits. The research team hopes to find a link between bone growth genes and the development of osteosarcoma in children.
Researchers identified a critical molecular pathway in osteosarcoma, finding it also present in cats and dogs. This discovery could lead to advances in palliative care for companion animals with skeletal tumors.
Children with cancer are vulnerable to bone fragility, exacerbated by sedentary behaviors and treatment side effects. Early management through exercise and bisphosphonates can mitigate this risk.
A study found that childhood cancer survivors are at a higher risk of developing secondary sarcomas, such as soft tissue sarcomas and osteosarcoma, with an average latency period of 11 years after primary diagnosis. Radiation therapy is associated with this increased risk.
Researchers found that retreatment with decitabine resulted in 45% of patients achieving any response, with some experiencing partial or complete remission. The median overall survival was 28 months, and continued outpatient maintenance treatment is being studied for its benefits.
A study of 11,481 childhood cancer survivors found that 20% had physical performance limitations compared to 12% of their siblings. Rehabilitation programs improved survival rates after heart attacks by reducing subsequent heart attacks by 17%.
A randomized trial of 900 patients with breast or prostate cancer found that a shorter course of radiation therapy was as effective as the standard treatment in providing pain relief. The study also showed less acute toxicity and re-treatment rates in patients who received a single dose of 8 Gy radiation.